Skip to main
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. has demonstrated a robust financial performance with shares experiencing a notable increase of approximately 7% in the after-market, attributed to strong Q4 results and optimistic revenue guidance. The company's operating margin expansion of at least 750 basis points suggests an operating margin exceeding 16%, indicating improved profitability. Additionally, potential growth drivers such as new product launches, faster adoption rates in heart and lung transplants, and international market expansion present significant opportunities for sustained financial performance and value creation in the years ahead.

Bears say

TransMedics Group Inc. is experiencing a decline in operating margins, projected to decrease by 250 basis points due to substantial investments in its clinical pipeline and international infrastructure. Additionally, despite achieving a year-over-year increase in product revenues of 33.1% and service revenues of 30.9%, the company's gross margins fell to 58.1%, which is 230 basis points below expectations. Further complicating the outlook are risks related to the potential for disappointing adoption rates of the Organ Care System (OCS), increasing competition leading to market share losses, and possible reimbursement changes that could negatively impact demand for the company's products and services.

TMDX has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 9 analysts, TMDX has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $154, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $154, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.